- Home
- TRUE vs PLX Comparison
TRUE vs PLX Comparison
Compare TRUE & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUE
- PLX
- Stock Information
- Founded
- TRUE 2005
- PLX 1993
- Country
- TRUE United States
- PLX United States
- Employees
- TRUE N/A
- PLX N/A
- Industry
- TRUE Computer Software: Programming Data Processing
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRUE Technology
- PLX Health Care
- Exchange
- TRUE Nasdaq
- PLX Nasdaq
- Market Cap
- TRUE 175.1M
- PLX 204.9M
- IPO Year
- TRUE 2014
- PLX 1998
- Fundamental
- Price
- TRUE $2.20
- PLX $2.37
- Analyst Decision
- TRUE Hold
- PLX Strong Buy
- Analyst Count
- TRUE 6
- PLX 1
- Target Price
- TRUE $3.68
- PLX $15.00
- AVG Volume (30 Days)
- TRUE 1.4M
- PLX 1.1M
- Earning Date
- TRUE 11-06-2025
- PLX 11-14-2025
- Dividend Yield
- TRUE N/A
- PLX N/A
- EPS Growth
- TRUE N/A
- PLX N/A
- EPS
- TRUE N/A
- PLX 0.08
- Revenue
- TRUE $184,559,000.00
- PLX $61,948,000.00
- Revenue This Year
- TRUE $9.14
- PLX $14.53
- Revenue Next Year
- TRUE $7.47
- PLX $75.77
- P/E Ratio
- TRUE N/A
- PLX $30.60
- Revenue Growth
- TRUE 11.66
- PLX 62.79
- 52 Week Low
- TRUE $1.05
- PLX $1.14
- 52 Week High
- TRUE $4.62
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- TRUE 52.32
- PLX 54.93
- Support Level
- TRUE $2.26
- PLX $2.22
- Resistance Level
- TRUE $2.48
- PLX $2.45
- Average True Range (ATR)
- TRUE 0.08
- PLX 0.17
- MACD
- TRUE 0.01
- PLX -0.02
- Stochastic Oscillator
- TRUE 73.21
- PLX 81.05
About TRUE TrueCar Inc.
TrueCar Inc is a data-driven online platform operating on common technology infrastructure, powered by proprietary data and analytics. It also customizes and operates its platform for affinity group marketing partners, including financial institutions like PenFed and American Express; membership-based organizations like Consumer Reports, AARP, Sam's Club, and AAA; and employee buying programs for large enterprises such as IBM and Walmart. The Company has one operating segment, with three distinct service offerings: Dealer products and services, OEM incentives, and other.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.